The dismissal of breach-of-contract claims removes the most direct liability theory, but the surviving unjust enrichment and Chapter 93A claims keep $14.3M in potential exposure alive. Monitor for summary judgment motions on the remaining claims and any settlement discussions, as the case now hinges on equitable rather than contractual theories.
Price Chart
Executive Summary
Collegium Pharmaceutical won partial dismissal of Walgreens' breach-of-contract lawsuit in Massachusetts federal court. The court dismissed Walgreens' breach of contract and implied covenant claims (Counts I and II) with prejudice, finding no contractual relationship existed between the parties. However, Walgreens' unjust enrichment claim (Count IV) and Massachusetts Chapter 93A unfair/deceptive trade practices claim (Count III) survived the motion to dismiss, with Walgreens seeking $14.3 million in damages for allegedly delayed product returns. The case proceeds on these two claims, creating ongoing litigation risk but removing the most direct contractual liability exposure.
Court Ruling Details
Key Facts
- Court dismissed breach of contract (Count I) and implied covenant (Count II) claims against Collegium, finding no enforceable contract existed between Walgreens and Collegium.
- Walgreens' unjust enrichment claim (Count IV) survived, alleging Collegium retained $14,321,229.99 in value from products Walgreens could not return due to delayed Form 222 authorizations.
- Walgreens' Chapter 93A unfair/deceptive trade practices claim (Count III) survived the motion to dismiss.
- The case was originally filed in June 2025 in Illinois, dismissed for lack of personal jurisdiction in February 2026, and refiled in Massachusetts in March 2026.
- Collegium's statute of limitations defense was not resolved at this stage, with the court noting factual questions remain about when the alleged misconduct occurred.
Financial Impact
Walgreens seeks $14.3 million in damages for allegedly unreturned product value; Collegium faces ongoing litigation costs and potential liability on two surviving claims
Risk Factors
- $14.3 million in potential damages on surviving unjust enrichment and Chapter 93A claims
- Ongoing litigation costs and management distraction
- Chapter 93A claim carries potential for treble damages and attorneys' fees if Collegium loses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-f9fa049eaf-COLL |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Court Ruling | $28.74 $22.38 | ▼ −22.13% | ▼ −20.18% | $22.07 (−23.21%) |
Aug 13, 2026 7w ago | 8-K | $28.15 $22.75 | ▼ −19.18% | ▼ −17.44% | $22.07 (−21.60%) |
Aug 6, 2026 8w ago | 8-K | $29.11 $23.70 | ▼ −18.58% | ▼ −19.18% | $22.07 (−24.18%) |
May 15, 2026 19w ago | Insider Cluster | $33.65 $34.65 | ▲ +2.97% | ▲ +1.39% | $22.07 (−34.41%) |
May 12, 2026 20w ago | Press Release | $35.69 $34.80 | ▼ −2.49% | ▼ −0.77% | $22.07 (−38.16%) |
May 11, 2026 20w ago | 144 | $35.81 $34.40 | ▼ −3.94% | ▼ −3.63% | $22.07 (−38.37%) |
Apr 23, 2026 23w ago | Press Release | $32.28 $34.22 | ▲ +6.01% | ▲ +1.38% | $22.07 (−31.63%) |
Apr 7, 2026 25w ago | 8-K | $33.43 $35.32 | ▲ +5.65% | ▼ −2.89% | $22.07 (−33.98%) |
Mar 19, 2026 28w ago | Press Release | $36.30 $34.41 | ▼ −5.21% | ▼ −12.83% | $22.07 (−39.20%) |
Mar 3, 2026 30w ago | Press Release | $39.99 $33.07 | ▼ −17.30% | ▼ −12.90% | $22.07 (−44.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access